Abstract
Afatinib is an irreversible tyrosine kinase inhibitor of the ErbB family, approved for the treatment of patients with non-small cell lung cancer with EGFR-sensitizing mutations. Like other EGFR inhibitors, afatinib can provoke adverse events such as diarrhoea, rash, paronychia or mucositis. The correct management of these adverse events is essential to maintain quality of life in these patients and obtain the maximum benefit from afatinib therapy. This study aimed to review the toxicity of the drug and summarize recommendations for the prevention and treatment of the most significant adverse events associated with afatinib.
Keywords:
Adverse effects; Afatinib; Cáncer de pulmón; EGFR; Efectos adversos; Lung cancer; Toxicidad; Toxicity.
Copyright © 2016 Elsevier España, S.L.U. All rights reserved.
MeSH terms
-
Afatinib
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Biomarkers, Tumor / antagonists & inhibitors*
-
Biomarkers, Tumor / genetics
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / metabolism
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / genetics
-
Genes, erbB
-
Genetic Markers
-
Humans
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / metabolism
-
Mutation
-
Protein Kinase Inhibitors / adverse effects*
-
Protein Kinase Inhibitors / therapeutic use
-
Quinazolines / adverse effects*
-
Quinazolines / therapeutic use
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Biomarkers, Tumor
-
Genetic Markers
-
Protein Kinase Inhibitors
-
Quinazolines
-
Afatinib
-
ErbB Receptors